表紙
市場調查報告書

女性不孕症治療藥的全球市場:2019年∼2023年

Global Female Infertility Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 905960
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
Back to Top
女性不孕症治療藥的全球市場:2019年∼2023年 Global Female Infertility Drugs Market 2019-2023
出版日期: 2019年08月01日內容資訊: 英文 129 Pages
簡介

全球女性不孕症治療藥市場,女性不孕症的高盛行率,女性不孕症的高風險因素,及有害轉換期高額的非藥物療法等成為市場成長促進因素,在預測期間內預計將以5%以上的年複合成長率擴大。但,替代治療選擇的利用可能性,品質評價低的後期開發平台,及嚴格法規等,可能妨礙在預測期間內女性不孕症治療藥產業的成長。

本報告提供全球女性不孕症治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各RoA

  • 市場區隔:各RoA
  • 各RoA比較:市場規模及預測(2018年∼2023年)
  • 非口服
  • 口服
  • 其他
  • 市場機會:各RoA

第7章 客戶形勢

第8章 各地區景觀

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 女性的不孕相關意識的高漲
  • 患者支援計劃
  • 生物相似藥的引進

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31566

About this market

Technavio's female infertility drugs market analysis considers sales from segments including parenteral, oral, and others. Our analysis also considers the sales of female infertility drugs in Asia, Europe, North America, and ROW. In 2018, the parenteral segment had a significant market share, and this trend is expected to continue over the forecast period. The parenteral route is more convenient for peptide drugs. This factor will play a significant role in the parenteral segment to maintain its market position. Also, our global female infertility drugs market report looks at factors such as the high prevalence of female infertility, high-risk factors for female infertility, and adverse outcomes and high cost of non-therapeutics. However, the availability of alternative treatment options, weak late-stage pipeline, and stringent regulations may hamper the growth of the female infertility drugs industry over the forecast period.

Overview

Adverse outcomes and high cost of non-therapeutics

Non-therapeutics such as ART procedures, ICSI, IUI, crypto preservation of gametes and embryos, and IVF are expensive. Also, the cost burden on patients in the US is high due to lack of insurance coverage. These factors will boost the demand for female infertility drugs and lead to the expansion of the global female infertility drugs market at a CAGR of over 5% during the forecast period.

Introduction of biosimilars

Biosimilars are identical copies of original biologics, which are highly expensive. This is driving the demand for biosimilars. In addition, they are gaining traction in the market because they promote patient adherence. This factor is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global female infertility drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global female infertility drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female infertility drugs manufacturers, that include Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, and Sanofi.

Also, the female infertility drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing awareness about female infertility
  • Patient assistance programs
  • Introduction of biosimilars

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: RoA - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by RoA
  • Exhibit 19: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by RoA
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Number of STD cases in US 2017
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Prevalence of infertility in some Indian states
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Some of the health problems associated with the use of ART
  • Exhibit 46: Pipeline molecules for treatment of female infertility: Overview
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Cost comparison of follitropin alfa
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendors covered
  • Exhibit 52: Vendor classification
  • Exhibit 53: Market positioning of vendors
  • Exhibit 54: Allergan Plc - Vendor overview
  • Exhibit 55: Allergan Plc - Product segments
  • Exhibit 56: Allergan Plc - Organizational developments
  • Exhibit 57: Allergan Plc - Geographic focus
  • Exhibit 58: Allergan Plc - Segment focus
  • Exhibit 59: Allergan Plc - Key offerings
  • Exhibit 60: Allergan Plc - Key customers
  • Exhibit 61: Ferring BV - Vendor overview
  • Exhibit 62: Ferring BV - Product segments
  • Exhibit 63: Ferring BV - Organizational developments
  • Exhibit 64: Ferring BV - Key offerings
  • Exhibit 65: Ferring BV - Key customers
  • Exhibit 66: Merck KGaA - Vendor overview
  • Exhibit 67: Merck KGaA - Business segments
  • Exhibit 68: Merck KGaA - Organizational developments
  • Exhibit 69: Merck KGaA - Geographic focus
  • Exhibit 70: Merck KGaA - Segment focus
  • Exhibit 71: Merck KGaA - Key offerings
  • Exhibit 72: Merck KGaA - Key customers
  • Exhibit 73: Novartis AG - Vendor overview
  • Exhibit 74: Novartis AG - Business segments
  • Exhibit 75: Novartis AG - Organizational developments
  • Exhibit 76: Novartis AG - Geographic focus
  • Exhibit 77: Novartis AG - Segment focus
  • Exhibit 78: Novartis AG - Key offerings
  • Exhibit 79: Novartis AG - Key customers
  • Exhibit 80: Sanofi - Vendor overview
  • Exhibit 81: Sanofi - Business segments
  • Exhibit 82: Sanofi - Organizational developments
  • Exhibit 83: Sanofi - Geographic focus
  • Exhibit 84: Sanofi - Segment focus
  • Exhibit 85: Sanofi - Key offerings
  • Exhibit 86: Sanofi - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: Definition of market positioning of vendors
Back to Top